Total medical devices industry M&A deals worth $1.2bn were announced in North America in May 2021, led by Allergan Aesthetics’ $550m acquisition of Soliton, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked a decrease of 56.6% over the previous month of $2.72bn and a drop of 79.2% when compared with the last 12-month average of $5.67bn.
North America held a 37.34% share of the global medical devices industry M&A deal value that totalled $3.16bn in May 2021. With a 36.39% share and deals worth $1.15bn, the US was the top country in North America’s M&A deal value across medical devices industry.
In terms of M&A deal activity, North America recorded 21 deals during May 2021, marking a decrease of 12.50% over the previous month and a rise of 5.00% over the 12-month average. The US recorded 20 deals during the month.
North America medical devices industry M&A deals in May 2021: Top deals
The top five medical devices industry M&A deals accounted for 95.3% of the overall value during May 2021.
The combined value of the top five medical devices deals stood at $1.13bn, against the overall value of $1.2bn recorded for the month.
The top five medical devices industry M&A deals of May 2021 tracked by GlobalData were:
1) Allergan Aesthetics’ $550m acquisition of Soliton
3) Roman Health Ventures’ $225m acquisition of Modern Fertility
4) The $60m acquisition of OBP Medical by CooperSurgical
5) Exact Sciences’ acquisition of 90% stake in PFS Genomics for $30.6m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.